NIH-CSR <script type="text/javascript"> var wmNotice = "UNT Web Archive - External links, forms, and search boxes may not function within this collection. Url: http://cms.csr.nih.gov/PeerReviewMeetings/CSRIRGDescription/ONCIRG/CDP.htm time: 14:06:03 Sep 20, 2008"; var wmHideNotice = "hide"; var contextRoot = "https://webarchive.library.unt.edu/eot2008/"; </script> <script type="text/javascript" src="https://webarchive.library.unt.edu/eot2008/js/disclaim.js"></script> <span id="Postingname3_PostingDisplayName">Chemo/Dietary Prevention Study Section [CDP]</span> (ONCIRG)

[CDP Roster]

The Chemo/Dietary Prevention Study Section reviews grant applications that address nutrition, dietary and chemopreventive factors and their use in intervention for modulation of cancer risk, and inhibition of cancer progression. This study section reviews grant applications dealing with basic mechanistic studies, preclinical and clinical (phase-1 and phase-2) studies as well as discovery, evaluation, and validation of biomarkers.

Specific areas covered by CDP include:

Discovery and evaluation of diets as well as individual dietary factors, chemopreventive agents, and targets for the modulation of cancer.
Mechanisms of cancer modulation by chemical and nutritional factors studied at the biochemical, molecular, and cellular levels.
Preclinical prevention studies (including in vitro and in vivo evaluation of efficacy and safety).
Phase-1 and Phase-2 clinical trials of chemopreventive agents.
Development and validation of markers important in prevention, including markers of cancer risk and progression.
Design, development, and synthesis of preventive agents.
Design and development of approaches to the prevention of tumors via other factors, such as exercise or vaccines.
Diet restriction, antioxidant defense mechanisms, DNA methylation, traditional (e.g., arytenoids, selenium, vitamins) and other food components.
In vitro and in vivo pharmacokinetic and pharmacodynamic studies of chemopreventive agents.
Effect of dietary factors on hormonal carcinogenesis, chemical carcinogenesis, differentiation/transdifferentiation, apoptosis, and oxidative stress

CDP has the following shared interests within the ONC IRG:

With Cancer Etiology [CE] in studies of mechanisms of cancer initiation: When the emphasis is on cancer prevention, the application could be assigned to CDP.
With Cancer Genetics [CG] in the role of gene polymorphisms: When the emphasis is on cancer prevention, the application could be assigned to CDP.
With Tumor Cell Biology [TCB] in studies of biological markers of cancer and mechanisms of tumor progression: When the emphasis is on cancer prevention, the application could be assigned to CDP.
With Cancer Biomarkers [CBSS] in proposals to discover, or validate biomarkers for cancer: When the emphasis is on cancer prevention, the application could be assigned to CDP.
With Cancer Immunopathology and Immunotherapy [CII] in applications dealing with cancer vaccines and immunological agents: When the emphasis is on cancer prevention, the application could be assigned to CDP.
With Drug Discovery and Molecular Pharmacology [DMP] in applications proposing synthesis, isolation, evaluation and validation of new drugs: When the emphasis is on cancer prevention, the application could be assigned to CDP.
With Clinical Oncology [CONC] in applications proposing phase I and II trials and in the development of chemopreventive drugs: When the emphasis is on cancer prevention, the application may be assigned to CDP.

CDP has the following shared interests outside the ONC IRG:

With the Biological Chemistry and Macromolecular Biophysics [BCMB] IRG: In general, research on the chemistry and synthesis of new agents/drugs could be assigned to BCMB; when the emphasis is on cancer prevention, the application could be assigned to CDP.
With the Health of the Population [HOP] IRG: HOP reviews applications dealing with cancer prevention that involve a community-based approach, (e.g., use of mass media to increase use of sunscreen, culturally tailored approaches to increase screening compliance).
With the Risk, Prevention and Health Behavior [RPHB] IRG: Studies of human behaviors that relate to cancer risk and the development of behavioral approaches to cancer prevention could be assigned to RPHB.
With organ-specific IRGs that deal with health and disease of particular organs/tissues: In general, when the emphasis is on cancer prevention, the application could be assigned to CDP.
With the Endocrinology, Metabolism, Nutrition and Reproductive Sciences [EMNR] IRG: Studies focusing on insulin resistance or obesity as a risk factor for cancer could be assigned to EMNR.